SAV1 and plasma cell myeloma: Taken together, ALKBH5 inhibition could increase SAV1 m6A levels, suppressed the HIPPO signalling pathway and ultimately activates the transcription factor YAP in myeloma cells, promoted the expression of P21, PUMA and BAX, exerting an anti-myeloma effect in vivo and in vitro.